92 related articles for article (PubMed ID: 25645980)
1. The auto-inhibitory state of Rho guanine nucleotide exchange factor ARHGEF5/TIM can be relieved by targeting its SH3 domain with rationally designed peptide aptamers.
He P; Tan DL; Liu HX; Lv FL; Wu W
Biochimie; 2015 Apr; 111():10-8. PubMed ID: 25645980
[TBL] [Abstract][Full Text] [Related]
2. Exploring the systematic effect of N-substituted PxxP motifs on peptoid affinity to ARHGEF5/TIM SH3 domain and its relationship with ARHGEF5/TIM activation.
Fu Y; He P; Zhou Y; Huang S; Liang L; Liu S
Proteins; 2019 Nov; 87(11):979-991. PubMed ID: 31197859
[TBL] [Abstract][Full Text] [Related]
3. Targeting rho guanine nucleotide exchange factor ARHGEF5/TIM with auto-inhibitory peptides in human breast cancer.
Huang O; Wu D; Xie F; Lin L; Wang X; Jiang M; Li Y; Chen W; Shen K; Hu X
Amino Acids; 2015 Jun; 47(6):1239-46. PubMed ID: 25743165
[TBL] [Abstract][Full Text] [Related]
4. The guanine nucleotide exchange factor Arhgef5 plays crucial roles in Src-induced podosome formation.
Kuroiwa M; Oneyama C; Nada S; Okada M
J Cell Sci; 2011 May; 124(Pt 10):1726-38. PubMed ID: 21525037
[TBL] [Abstract][Full Text] [Related]
5. Targeting the SH3 domain of human osteoclast-stimulating factor with rationally designed peptoid inhibitors.
Han S; Liu Q; Wang F; Yuan Z
J Pept Sci; 2016 Aug; 22(8):533-9. PubMed ID: 27443979
[TBL] [Abstract][Full Text] [Related]
6. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
Zhou P; Hou S; Bai Z; Li Z; Wang H; Chen Z; Meng Y
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1122-1131. PubMed ID: 28754059
[TBL] [Abstract][Full Text] [Related]
7. Role of the C-terminal SH3 domain and N-terminal tyrosine phosphorylation in regulation of Tim and related Dbl-family proteins.
Yohe ME; Rossman K; Sondek J
Biochemistry; 2008 Jul; 47(26):6827-39. PubMed ID: 18537266
[TBL] [Abstract][Full Text] [Related]
8. Expression and molecular characterization of alternative transcripts of the ARHGEF5/TIM oncogene specific for human breast cancer.
Debily MA; Camarca A; Ciullo M; Mayer C; El Marhomy S; Ba I; Jalil A; Anzisi A; Guardiola J; Piatier-Tonneau D
Hum Mol Genet; 2004 Feb; 13(3):323-34. PubMed ID: 14662653
[TBL] [Abstract][Full Text] [Related]
9. Auto-inhibition of the Dbl family protein Tim by an N-terminal helical motif.
Yohe ME; Rossman KL; Gardner OS; Karnoub AE; Snyder JT; Gershburg S; Graves LM; Der CJ; Sondek J
J Biol Chem; 2007 May; 282(18):13813-23. PubMed ID: 17337446
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of the differential binding of the SH3 domains of Grb2 adaptor to the guanine nucleotide exchange factor Sos1.
McDonald CB; Seldeen KL; Deegan BJ; Farooq A
Arch Biochem Biophys; 2008 Nov; 479(1):52-62. PubMed ID: 18778683
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the SH3 domain of betaPIX in complex with a high affinity peptide from PAK2.
Hoelz A; Janz JM; Lawrie SD; Corwin B; Lee A; Sakmar TP
J Mol Biol; 2006 Apr; 358(2):509-22. PubMed ID: 16527308
[TBL] [Abstract][Full Text] [Related]
12. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the rac activator, Asef, reveals its autoinhibitory mechanism.
Murayama K; Shirouzu M; Kawasaki Y; Kato-Murayama M; Hanawa-Suetsugu K; Sakamoto A; Katsura Y; Suenaga A; Toyama M; Terada T; Taiji M; Akiyama T; Yokoyama S
J Biol Chem; 2007 Feb; 282(7):4238-4242. PubMed ID: 17190834
[TBL] [Abstract][Full Text] [Related]
14. Why ligand cross-reactivity is high within peptide recognition domain families? A case study on human c-Src SH3 domain.
He P; Wu W; Wang HD; Liao KL; Zhang W; Lv FL; Yang K
J Theor Biol; 2014 Jan; 340():30-7. PubMed ID: 24021866
[TBL] [Abstract][Full Text] [Related]
15. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2.
Xu XX; Yi T; Tang B; Lambeth JD
Oncogene; 1998 Mar; 16(12):1561-9. PubMed ID: 9569023
[TBL] [Abstract][Full Text] [Related]
16. Prediction of binding affinities between the human amphiphysin-1 SH3 domain and its peptide ligands using homology modeling, molecular dynamics and molecular field analysis.
Hou T; McLaughlin W; Lu B; Chen K; Wang W
J Proteome Res; 2006 Jan; 5(1):32-43. PubMed ID: 16396493
[TBL] [Abstract][Full Text] [Related]
17. The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity.
Wisniewska M; Bossenmaier B; Georges G; Hesse F; Dangl M; Künkele KP; Ioannidis I; Huber R; Engh RA
J Mol Biol; 2005 Apr; 347(5):1005-14. PubMed ID: 15784259
[TBL] [Abstract][Full Text] [Related]
18. The crystal structure of the N-terminal SH3 domain of Grb2.
Guruprasad L; Dhanaraj V; Timm D; Blundell TL; Gout I; Waterfield MD
J Mol Biol; 1995 May; 248(4):856-66. PubMed ID: 7752246
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of the SH3 domain of beta-PIX and its interaction with alpha-p21 activated kinase (PAK).
Mott HR; Nietlispach D; Evetts KA; Owen D
Biochemistry; 2005 Aug; 44(33):10977-83. PubMed ID: 16101281
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains.
Lim WA; Richards FM; Fox RO
Nature; 1994 Nov; 372(6504):375-9. PubMed ID: 7802869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
